Stock Markets July 7, 2026 08:39 AM

Wolfe Research Opens Coverage on Ferrari at Outperform, Sees Upside from New Models

Analyst Emmanuel Rosner projects above-consensus 2027 revenue and strong margins as Ferrari renews its lineup and moderates its electrification approach

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
RACE

Wolfe Research initiated coverage of Ferrari with an Outperform rating and a €382 price target, saying the luxury automaker’s public growth targets are conservative. Analyst Emmanuel Rosner expects new model pricing to accelerate revenue beginning in 2027 and projects higher sales and EBIT than consensus for fiscal 2027, while describing electrification concerns as overblown.

Wolfe Research Opens Coverage on Ferrari at Outperform, Sees Upside from New Models
RACE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Wolfe Research initiated coverage of Ferrari with an Outperform rating and a €382 price target, citing conservative company growth targets.
  • Analyst Emmanuel Rosner expects new model pricing to accelerate Ferrari’s topline starting in 2027 and further as the lineup is fully renewed by 2030.
  • Wolfe forecasts fiscal 2027 sales of €8.47 billion and EBIT of €2.62 billion, above consensus, and projects average selling prices of €550,000+ by 2030 supporting >6% top-line CAGR and ~31% EBIT margin.

Wolfe Research began coverage of Ferrari on Tuesday, assigning the luxury automaker an Outperform rating and setting a price target of €382. The firm's analyst, Emmanuel Rosner, argued that Ferrari’s published growth goals understate potential upside and that planned model introductions will lift revenue growth above consensus starting in 2027.

Rosner noted that Ferrari "has significantly underperformed since its 2025 Capital Markets Day," when the company outlined a 5% compound annual growth rate target for 2025-2030 that fell short of investor expectations. Despite that reaction, he said there is "room to exceed its targets, as pricing of new models drives topline acceleration in 2027 and even more so when the entire model lineup is fully renewed by 2030."

Wolfe Research’s financial projections place fiscal 2027 sales at €8.47 billion and EBIT at €2.62 billion, both above consensus figures of €8.13 billion and €2.44 billion, respectively. The firm expects average selling prices to reach €550,000 or higher by 2030, a level that supports a top-line compound annual growth rate in excess of 6% and an EBIT margin near 31% by that year.

Addressing market worries about Ferrari’s transition to electrified powertrains, Rosner described such concerns as "overblown." He highlighted that the company "has learned important lessons from its initial electrified vehicles" and plans a more measured approach to powertrain strategy going forward. He added that investments in electrification "are now in the rear-view mirror."

Wolfe’s €382 target derives from applying a 33-times multiple to its above-consensus fiscal 2027 EPS estimate of €11.59, which the firm says implies roughly 13% upside to the current share price. Rosner also observed that if Ferrari’s price-to-earnings multiple were to recover toward its five-year average of 40 times, there would be "considerable additional upside."


Impacted sectors: luxury automotive, automotive manufacturing, equity markets tracking premium carmakers.

Risks

  • Market reaction to Ferrari’s publicly stated 5% CAGR target for 2025-2030 has already led to underperformance - equity market sentiment remains a risk for valuation.
  • Uncertainty around the pace and reception of model launches - upside depends on pricing and commercial performance of new models starting in 2027.
  • Perspectives on electrification could remain a source of volatility if investor concerns persist, despite the analyst’s view that such fears are "overblown."

More from Stock Markets

InsuranceDekho Parent Taps Global and Local Banks for Potential $400 Million IPO Jul 7, 2026 Compass Pathways Shares Drop After Six-Month COMP006 Results Jul 7, 2026 DigitalOcean Forecast Spurs 12% Rally as Customer Contracts and RPO Climb Sharply Jul 7, 2026 Turn Therapeutics Expands Atopic Dermatitis Phase 2 Trial After Positive Interim Readout Jul 7, 2026 Eos Energy Advances After Frontier Power Selects Four Long-Duration Battery Projects Jul 7, 2026